Multiple sclerosis management during the COVID-19 pandemic

Brandon P Moss, Kedar R Mahajan, Robert A Bermel, Kelsey Hellisz, Le H Hua, Timothy Hudec, Scott Husak, Marisa P McGinley, Daniel Ontaneda, Zhini Wang, Malory Weber, Paula Tagliani, Simón Cárdenas-Robledo, Ana Zabalza, Georgina Arrambide, Pere Carbonell-Mirabent, Marta Rodriguez-Barranco, Jaume Sastre-Garriga, Mar Tintore, Xavier Montalban, Morgan Douglas, Esther Ogbuokiri, Berna Aravidis, Jeffrey A Cohen, Ellen M Mowry and Kathryn C Fitzgerald

Abstract

Background: People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services.

Objectives: To evaluate risk factors for COVID-19 susceptibility and describe the pandemic’s impact on healthcare delivery.

Methods: Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d’Hebron-Centre d’Esclerosis Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care.

Results: There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services.

Conclusion: Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.

Keywords: COVID-19, SARS-CoV-2, multiple sclerosis, disease modifying therapies, health behaviors, healthcare delivery

Date received: 7 July 2020; accepted: 13 July 2020.

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pandemic with a high case fatality rate (534,062 deaths out of 11,425,209 confirmed cases as of 7 July 2020) and is associated with unprecedented changes to daily life and delivery of healthcare.1 People with multiple sclerosis (MS), an inflammatory demyelinating and neurodegenerative disorder treated with immunomodulatory disease modifying therapies (DMTs), may be at higher risk than the general public due to neurologic disability,2 the impact of DMTs on COVID-19 susceptibility and severity, and the effects of SARS-CoV-2 on MS disease activity. Moreover, many people with MS need access to regular medical services (infusions, physical therapy, occupational therapy, botulinum toxin injections for spasticity, and homecare services), which could be disrupted by changes to healthcare delivery as a result of the COVID-19 pandemic.

To better understand the impact of COVID-19 on the MS population, three large MS centers in the United States (US) and Europe, the Cleveland Clinic Mellen
Center for MS Treatment and Research (CC), the Johns Hopkins MS Precision Medicine Center of Excellence (JH), and the Vall d’Hebron Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), sent a comprehensive survey to their respective clinic populations. The goals of the survey and the current manuscript are to evaluate candidate risk factors for COVID-19 susceptibility and describe the impact of the pandemic on routine MS management in a large international MS clinical population. Here we report the results from the first 3028 participants.

Materials and methods

Study design
This is a multicenter observational study combining survey data with detailed demographics, MS disease characteristics, and a battery of patient-reported outcome measures from clinical registries maintained at each participating institution. Sites prospectively coordinated data collection to ensure that key survey and registry data were consistent across institutions. This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guideline, the Declaration of Helsinki, and local ethical and legal requirements. Approval was obtained from the institutional review boards of each participating institution.

Study population
Participants were recruited from the clinic populations of CC, JH, and CEMCAT. Surveys were sent to adults age 18 and older, followed by a provider from one of the participating MS centers, with a clinical diagnosis of MS confirmed by chart review. Surveys were sent by email or secure electronic medical record communication. Survey data were collected and managed using REDCap electronic data capture tools hosted at each institution. Responders reported whether they had confirmed COVID-19 (viral symptoms with a positive SARS-CoV-2 test result) or, if untested, whether a healthcare provider suspected they had COVID-19.

All three MS centers are members of Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS), a learning health system sponsored by Biogen in collaboration with 10 healthcare institutions in the United States and Europe. MS PATHS sites use a tablet-based application to collect standardized patient data as part of routine clinical care.

Study assessments
Survey questionnaires sent in April and May of 2020 collected core information regarding living situation, comorbidities, current DMT use, smoking and drug use, work and home exposure risks, travel, recent illness and symptoms, SARS-CoV-2 testing, and COVID-19 outcomes and treatments from all sites. Additional information about use of immunomodulatory therapies for conditions other than MS, health behaviors (social distancing, mask use, and number of weekly contacts outside the home), and the presence of a relapse or worsening MS symptoms associated with COVID-19 illness were collected by CC and JH. The impact of the pandemic on routine clinical care (delay, discontinuation, or modification of DMT use, and interruption of services) was collected by CC. A strict countrywide lockdown was in place for Spain at the time of survey completion, only allowing people to leave their homes to buy food and medicine, to work, and to care for minors, the elderly, and other vulnerable people. As a result, social distancing practices were not expected to vary widely, and questions about health behaviors were omitted from the CEMCAT survey.

Clinical practice registries contained demographics (age, sex, race, ethnicity, and indicators of socioeconomic status (SES)), information about MS disease history and treatment (disease duration, disease course, and current and prior DMTs), and measures of disability. Disability was assessed by the Expanded Disability Status Scale (EDSS), the most commonly used measure of MS-related disability, or the Patient Determined Disease Steps (PDDS), a validated self-report measure of MS disability strongly correlated with the EDSS. Indicators of SES included years of education and the Area Deprivation Index (ADI) for the US sites. The ADI is a composite measure that incorporates 17 different measures of SES derived using geo-coded addresses; nationwide indices range from 0 (least disadvantaged) to 100 (most disadvantaged).

Statistical methods and data analysis
Baseline demographics, disease characteristics, and key comorbidities were reported with descriptive statistics (mean and standard deviation for continuous variables and frequency and percentage for categorical variables). Differences between survey responders and non-responders; participants with and without suspicion of having COVID-19; and SARS-CoV-2 positive and negative cases were tested using logistic regression models. Predictors of non-adherence to health behaviors were assessed using univariate and multivariable-adjusted models performed with logistic regression...
methods. Similar analyses evaluated potential differences across sites via generalized linear models where appropriate. Statistical analysis was performed with the R software, version 3.6.2.8

Results
Of 10,816 people sent a questionnaire, 3028 (28%) finished the survey. Survey responders were predominantly female (75%) and white (90%) with relapsing MS (72%). Across surveys, responders were older, more likely to be female, more likely to be non-Hispanic whites, and had higher SES compared to non-responders.

Table 1 summarizes characteristics of responders by presence or absence of SARS-CoV-2 testing. For all responders, both tested and untested, 2334 (77%) were on a DMT, 200 (7%) were taking an immunomodulatory therapy for a condition other than MS, 448 (15%) were current smokers or vapers, and 1376 (45%) had a medical comorbidity suspected to be a risk factor for more severe COVID-19 (obesity, hypertension, chronic obstructive pulmonary disease (COPD), diabetes, asthma, other chronic lung disease, coronary artery disease, stroke, chronic kidney disease, cancer, other inflammatory disease, or HIV). Of those with a medical comorbidity suspected to be a risk factor for more severe COVID-19, obesity (28.8%) and hypertension (19.1%) were most common. Contact with a known positive COVID-19 case was relatively uncommon (1.8%).

Of 90 (3.0%) who reported having been tested for SARS-CoV-2, 17 (18.8%) reported having a positive test. Among those tested for SARS-CoV-2, there was a lower proportion of men (14.4% vs. 25.2%), higher proportion of people on immunomodulatory therapies for conditions other than MS (18.9% vs. 6.2%), and higher proportion of people with medical comorbidities (60.0% vs. 45.0%) compared to untested individuals.

There were 77 (2.5%) cases of suspected or confirmed COVID-19. Factors associated with suspected or confirmed COVID-19 are summarized in Table 2. Suspected or confirmed cases were more likely to have contact with someone with known COVID-19 (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54) or to live with someone with COVID-19 (OR: 13.94; 95% CI: 7.84, 24.80). For the US residents, there was also a higher proportion of African Americans (15.6% vs. 6.8%) and people of lower SES (ADI: 45.8 vs. 40.9), but these did not rise to the level of statistical significance (OR 2.56; 95% CI: 0.97, 6.77 and OR 1.05; 95% CI: 0.90, 1.22, respectively).

Suspected or confirmed COVID-19 was more prevalent for Spanish than the US residents (OR: 3.78; 95% CI: 2.31, 6.17).

For the 2270 (75%) responders who were US residents, the majority were strictly self-isolating, 1830 (81%), only leaving home to get basic necessities or to go to work if they could not work from home; left home infrequently (mean 1.52 (standard deviation (SD): 3.37)); and wore a mask when out in public, 1329 (59%). We also conducted analyses assessing predictors of non-adherence to health behaviors (social distancing, mask use in public, and limiting number of weekly contacts outside the home) (Table 3). In multivariable-adjusted models, individuals having to work on site, with lower education level, and residing in more socioeconomically disadvantaged areas were less likely to be following social distancing guidelines. Older individuals were more likely to follow social distancing guidelines. Predictors of social distancing were similar when stratified by site (CC vs. JH).

Of the 90 suspected or confirmed COVID-19 cases, 5 (5.6%) were hospitalized (1 from CC; 4 from CEMCAT). 67 (74.4%) were recovering or fully recovered at the time of the survey, while 3 (3.3%) had worsening symptoms or were recovering with complications.

Table 4 summarizes changes in MS management that occurred as a result of the COVID-19 pandemic and incorporates results pooled from JH and CC (n = 2270). 100 (4.4%) survey responders reported changes to their therapy plans. By far, the most common type of medication changes were delays in infusions (71.9%); 94.6% cite preventing COVID-19 as the reason for delay. Only half (51.2%) were advised to delay their infusion therapy by a healthcare provider.

With respect to effects on MS care, 351 (15.5%) reported a disruption to rehabilitative therapy (physical therapy, occupational therapy, or botulinum toxin injections), while 51 (2.2%) reported a disruption to homecare services. Those reporting disruption to rehabilitative therapy or homecare services were more likely to be older (mean age 55.7 vs. 51.3 years; \( p < 0.001 \)), have progressive MS (47.9% vs. 25.2%; \( p < 0.001 \)), have a walking aid (46.4% vs. 18.9% cane use; \( p < 0.001 \)), and have a comorbid condition (65.2% vs. 58.8%; \( p = 0.04 \)).

Discussion
The COVID-19 pandemic presents a unique challenge to people with MS given the immune pathogenesis of MS, use of treatments with immunomodulatory actions, and need for access to regular medical services.9 In
evaluating factors associated with suspected or confirmed COVID-19 illness, only contact with someone with known COVID-19 at home or in the community was significant, highlighting the importance of health behaviors to prevent infection.

Overall, there was good compliance with reported social distancing measures, with 83% of participants reporting strict self-isolation. However, individuals required to work on site, with lower education level, and residing in more socioeconomically disadvantaged areas were less likely to report following social distancing guidelines, whereas older individuals were more likely to report following social distancing guidelines. Younger people with a lower education level may be an important target for educational outreach regarding health risks of COVID-19 and appropriate health behaviors. Because these individuals had fewer opportunities to work from home, clinician support for work restrictions may be important for people with MS who lack job flexibility, especially if they have risk factors for severe COVID-19 illness as defined in smaller studies of MS populations2 and larger studies of non-MS populations.10–12

| COVID-19 testing status | Not tested | Tested | p value |
|-------------------------|------------|--------|---------|
| n                       | 2938       | 90     |         |
| Age, mean (SD)          | 50.31 (12.09) | 48.85 (12.42) | 0.26    |
| Male sex, n (%)         | 740 (25.2)  | 13 (14.4) | 0.03    |
| Race, n (%)             |           |        |         |
| White                   | 2644 (90.0) | 79 (87.8) | 0.35    |
| Black/African American  | 149 (5.1)  | 8 (8.9)  |         |
| Other                   | 67 (2.3)   | 2 (2.2)  |         |
| Unknown                 | 77 (2.6)   | 1 (1.1)  |         |
| Hispanic/Latino ethnicity | 61 (2.1) | 1 (1.1) | 0.80    |
| Area Deprivation Index, mean (SD)a | 41.03 (25.14) | 41.48 (25.21) | 0.88    |
| High school education or less, n (%)a | 316 (14.4) | 7 (9.2) | 0.27    |
| Disease duration, mean (SD) | 16.40 (11.14) | 17.50 (12.00) | 0.21    |
| RRMS, n (%)             | 2118 (72.1) | 70 (77.8) | 0.37    |
| PDDS, mean (SD)b        | 2.07 (2.22) | 1.68 (2.01) | 0.56    |
| EDSS, mean (SD)b        | 2.78 (2.00) | 2.19 (2.43) | 0.88    |
| DMT, n (%)              |           |        | 0.76    |
| Infusion                | 943 (33.3) | 31 (34.4) |        |
| Injectable              | 444 (15.7) | 10 (11.1) |        |
| None                    | 669 (23.6) | 25 (27.8) |        |
| Oral                    | 715 (25.3) | 22 (24.4) |        |
| Other                   | 59 (2.1)   | 2 (2.2)  |         |
| Not reported            | 97 (3.3)   | 0 (0.0)  |         |
| Other immunotherapy, n (%)a | 183 (6.2) | 17 (18.9) | <0.001  |
| Any comorbidity, n (%)c | 1322 (45.0) | 54 (60.0) | 0.007   |
| Current smoker or vaper, n (%)a | 433 (14.7) | 15 (16.7) | 0.72     |
| Working on site, n (%)a | 348 (15.9) | 18 (23.7) | 0.10    |
| Positive COVID-19 test, n (%) | – 17 |        |         |
| Contact with positive case, n (%) | 39 (1.7) | 15 (16.7) | <0.001  |
| Positive household contact, n (%) | 99 (3.4) | 12 (13.3) | <0.001  |

SD: standard deviation; RRMS: relapsing-remitting multiple sclerosis; PDDS: Patient Determined Disease Steps; EDSS: Expanded Disability Status Scale; DMT: disease modifying therapies.

aData available in CC and JH surveys (n = 2270).

bData available in CEMCAT survey (n = 758).

cAny comorbidity denotes having obesity, hypertension, COPD, diabetes, asthma, other lung diseases, coronary artery disease, stroke, chronic kidney disease, cancer, other inflammatory diseases, or HIV.
With regard to practice management, most individuals continued DMT dosing without intentional delays or discontinuations, consistent with National MS Society and MS International Federation guidelines. However, 5% of survey responders reported changes to their therapy plans, most commonly delays in Table 2.

| Table 2. Factors associated with suspected or confirmed COVID-19 in people with MS. |
|--------------------------------------------------|-------------------------------------------------|--------------------------------------------------|
|                                                   | No COVID-19 | Suspected or confirmed COVID-19 | OR (95% CI) for suspected or confirmed COVID-19 |
| N                                                 | 2951 | 77                              |                                                  |
| Site, n (%)                                        |       |                                 |                                                  |
| Cleveland Clinic                                   | 1557 | 26 (33.8)                       | 1.00 (ref)                                       |
| Johns Hopkins                                      | 681  | 6 (7.8)                         | 0.53 (0.22, 1.29)                                |
| CEMCAT                                            | 713  | 45 (58.4)                       | **3.78 (2.31, 6.17)**                            |
| Age, mean (SD)                                     | 50.36 | 46.79 (10.84)                   | 0.85 (0.63, 1.15)                                |
| Male sex, n (%)                                    | 738  | 15 (19.7)                       | 0.62 (0.35, 1.10)                                |
| Race, n (%)                                        |       |                                 |                                                  |
| White                                              | 2652 | 71 (92.2)                       | 1.00 (ref)                                       |
| Black/African American                             | 152  | 5 (6.5)                         | 2.56 (0.97, 6.77)                                |
| Other                                              | 68   | 1 (1.3)                         | 1.16 (0.15, 8.75)                                |
| Unknown                                            | 78   | 0 (0.0)                         | –                                               |
| Hispanic/Latino ethnicity, n (%)                   | 62   | 0 (0.0)                         | –                                               |
| Working on site, n (%)                             | 360  | 6 (18.8)                        | 1.14 (0.46, 2.79)                                |
| Area Deprivation Index, mean (SD)                  | 40.97| 45.91 (25.75)                   | 1.05 (0.90, 1.22)                                |
| High school education or less, n (%)               | 323  | 0 (0.0)                         | –                                               |
| RRMS, n (%)                                        | 2131 | 57 (24.0)                       | 1.04 (0.62, 1.75)                                |
| PDSS/EDSS, mean (SD)                               | 2.24 | 2.30 (1.97)                     | 0.95 (0.85, 1.07)                                |
| Disease duration, mean (SD)                        | 16.43| 16.60 (10.15)                   | 1.15 (0.93, 1.41)                                |
| DMT, n (%)                                         |       |                                 |                                                  |
| Injectable                                         | 438  | 16 (21.1)                       | 1.00 (ref)                                       |
| Infusion                                           | 949  | 25 (32.9)                       | 0.93 (0.49, 1.78)                                |
| None                                               | 684  | 10 (13.2)                       | 0.52 (0.23, 1.17)                                |
| Oral                                               | 714  | 23 (30.3)                       | 1.01 (0.52, 1.95)                                |
| Other                                              | 59   | 2 (2.6)                         | 0.79 (0.18, 3.58)                                |
| Number of times leaving home per week, mean (SD)   | 1.52 | 2.47 (11.44)                    | **1.07 (1.01, 1.14)**                            |
| Number of times household contacts leaving home per week, mean (SD) | 1.42 | 1.25 (2.16)                      | 0.97 (0.81, 1.15)                                |
| Not adhering to social distancing recommendations, n (%) | 432 | 8 (25.0)                      | 1.31 (0.58, 2.94)                                |
| Viral symptoms, n (%)                              | 782  | 71 (92.2)                       | 66.09 (27.84, 156.88)                            |
| Contact with positive case, n (%)                  | 38   | 16 (20.8)                       | **4.38 (1.04, 18.54)**                           |
| Positive household contact, n (%)                  | 83   | 28 (36.4)                       | **13.94 (7.84, 24.80)**                          |
| Any comorbidity, n (%)                             | 1339 | 37 (50.0)                       | **1.83 (1.09, 3.07)**                            |
| Current smoker or vaper, n (%)                     | 432  | 16 (21.1)                       | 1.45 (0.82, 2.57)                                |

SD: standard deviation; CI: confidence interval; RRMS: relapsing-remitting multiple sclerosis; PDSS: Patient Determined Disease Steps; EDSS: Expanded Disability Status Scale; DMT: disease modifying therapies.

*Denotes individuals who were confirmed positive cases and those who were suspected by a healthcare professional of ever having COVID-19 but were never tested.
*OR are adjusted for location of suspected or confirmed COVID-19 case. Because of the relatively limited number of cases and cases were not distributed with equal frequency across centers, we did not perform extensive multivariable-adjusted analyses.
*Data for these variables were pooled from JH and CC surveys only (n = 2270, 32 with suspected or confirmed COVID-19).
*OR for age represents a per 10-year increase; OR for ADI represents a per 10 percentile increase in deprivation.
*Any comorbidity denotes having obesity, hypertension, COPD, diabetes, asthma, other lung diseases, coronary artery disease, stroke, chronic kidney disease, cancer, other inflammatory diseases, or HIV.
infusions. While most of these individuals were advised to delay their infusions, a large portion delayed their infusions for other reasons, possibly due to their own concerns about treatment during the COVID-19 pandemic and possibly due to interruptions of care. There was also a notable disruption of rehabilitative therapy and homecare services among survey responders. These findings are consistent with reports of disruptions in health services for other non-communicable diseases.\textsuperscript{15} Interruptions to these services could have downstream consequences for MS-related outcomes and other aspects of health-related quality of life.

**Table 3.** Factors associated with differences in social distancing behavior.

| Characteristic                          | Strictly self-isolating | At least some in-person socializing | Univariate model | Multivariable-adjusted model\textsuperscript{a} |
|-----------------------------------------|-------------------------|------------------------------------|------------------|-----------------------------------------------|
| N                                       | 1830                    | 440                                |                  |                                               |
| Age, mean (SD)\textsuperscript{b}       | 52.44 (12.06)           | 50.01 (11.85)                      | 0.78 (0.68, 0.89)| 0.80 (0.65, 1.00)                             |
| Male sex                                | 405 (22.6)              | 115 (26.9)                         | 1.26 (0.99, 1.60)| 1.33 (0.99, 1.79)                             |
| Race                                    |                         |                                    |                  |                                               |
| White                                   | 1584 (86.6)             | 385 (87.5)                         | 1.00 (ref)       | 1.00 (ref)                                    |
| Black/African American                  | 127 (6.9)               | 30 (6.8)                           | 0.97 (0.64, 1.47)| 1.06 (0.65, 1.74)                             |
| Other                                   | 53 (2.9)                | 13 (3.0)                           | 1.01 (0.54, 1.87)| 0.99 (0.43, 2.28)                             |
| Unknown                                 | 66 (3.6)                | 12 (2.7)                           | 0.75 (0.40, 1.40)| 1.35 (0.60, 3.01)                             |
| Hispanic/Latino ethnicity               | 53 (3.0)                | 9 (2.0)                            | 0.70 (0.34, 1.43)| 0.62 (0.25, 1.57)                             |
| Area Deprivation Index, mean (SD)\textsuperscript{b} | 39.56 (24.92)          | 47.17 (25.13)                      | 1.13 (1.08, 1.17)| 1.13 (1.07, 1.20)                             |
| High school education or less           | 238 (13.0)              | 85 (19.3)                          | 1.60 (1.22, 2.10)| 1.54 (1.10, 2.17)                             |
| RRMS                                    | 1272 (71.0)             | 309 (72.5)                         | 1.07 (0.85, 1.36)| 1.08 (0.78, 1.50)                             |
| PDDS                                    | 2.09 (2.23)             | 1.91 (2.14)                        | 0.96 (0.92, 1.01)| 1.02 (0.94, 1.10)                             |
| Disease duration                        | 17.86 (11.52)           | 16.32 (10.97)                      | 0.88 (0.80, 0.97)| 1.02 (0.89, 1.18)                             |
| DMT                                     |                         |                                    |                  |                                               |
| Injectable                               | 242 (14.0)              | 40 (9.1)                           | 1.00 (ref)       | 1.00 (ref)                                    |
| Infusion                                | 609 (35.1)              | 162 (36.9)                         | 1.61 (1.10, 2.35)| 1.30 (0.82, 2.06)                             |
| None                                    | 451 (26.0)              | 94 (21.4)                          | 1.26 (0.84, 1.88)| 1.47 (0.91, 2.36)                             |
| Oral                                    | 408 (23.5)              | 134 (30.5)                         | 1.99 (1.35, 2.93)| 1.75 (1.10, 2.77)                             |
| Other                                   | 24 (1.4)                | 9 (2.1)                            | 2.27 (0.98, 5.23)| 2.86 (1.02, 8.01)                             |
| Wearing a mask when leaving the house   | 1086 (59.3)             | 243 (55.2)                         | 0.85 (0.69, 1.04)| 0.64 (0.49, 0.85)                             |
| Number of times leaving the house per week | 1.26 (2.76)             | 2.58 (4.93)                        | 1.11 (1.07, 1.14)| 1.12 (1.08, 1.17)                             |
| Any comorbidity\textsuperscript{c}      | 967 (59.8)              | 242 (60.2)                         | 1.02 (0.81, 1.27)| 1.03 (0.78, 1.35)                             |
| Current smoker or vaper                 | 255 (15.4)              | 87 (20.7)                          | 1.44 (1.09, 1.88)| 1.09 (0.78, 1.33)                             |

SD: standard deviation; CI: confidence interval; RRMS: relapsing-remitting multiple sclerosis; PDDS: Patient Determined Disease Steps; EDSS: Expanded Disability Status Scale; DMT: Disease Modifying Therapies.

\textsuperscript{a}Multivariable OR is adjusted for all factors included in the table.

\textsuperscript{b}OR for age represents a per 15-year increase; OR for ADI represents a per 10 percentile increase in deprivation.

\textsuperscript{c}Any comorbidity denotes having obesity, hypertension, COPD, diabetes, asthma, other lung diseases, coronary artery disease, stroke, chronic kidney disease, cancer, other inflammatory diseases, or HIV.

**Table 4.** Changes in MS management occurring as a result of COVID-19.

| Characteristic                          | N (%)          |
|-----------------------------------------|----------------|
| Disruption to rehabilitative therapy    | 355 (15.5)     |
| Disruption to homecare services         | 51 (2.2)       |
| Changed or adjusted MS therapy          | 100 (4.4)      |
| Type of medication change               |                |
| Changed                                 | 8 (8.2)        |
| Delay                                   | 71 (73.2)      |
| Stopped                                 | 18 (18.6)      |

MS: multiple sclerosis.
The relatively low proportion of tested individuals, potential for false negative polymerase chain reaction (PCR), and small number of cases makes estimation of COVID-19 prevalence and prevalence of adverse disease-related outcomes difficult, and, most likely, our survey missed those with the most severe outcomes. Nevertheless, of the 90 suspected or confirmed COVID-19 cases, there were few hospitalizations, and most reported having recovered or being fully recovered at the time of the survey. Larger ongoing registry studies will evaluate predictors of COVID-19 outcomes in people with MS.

Our study has certain limitations. As with any observational study, our survey is subject to ascertainment bias. Differences in the demographic characteristics of responders versus non-responders demonstrate some degree of ascertainment bias. In addition, more severe illness or hospitalization could have prevented prospective participants from responding. Even so, our findings were similar to a registry study of 11,672 individuals in the CC population at large, where men, African Americans, older individuals, and those with known COVID-19 exposure were at higher risk of testing positive for COVID-19.16

Ongoing surveys will facilitate case ascertainment and serve as a vehicle for future studies of change in behaviors over time and effects of the pandemic on patient-reported outcomes and MS disease management. Longitudinal follow-up will also allow assessment of the degree to which disruptions of care affect disease activity or severity independent of COVID-19.

Conclusion
Our findings suggest that exposure risks are the driver of COVID-19 infection in the MS population. Younger people with lower SES required to work on site may be at higher risk for exposure and are potential targets for educational intervention and clinician support for work restrictions to limit exposure. Providers should be mindful of potential delays of infusion therapies and disruption of MS care more generally.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ms B.A. has nothing to disclose. Dr G.A. has received compensation for consulting services or participation in advisory boards from Sanofi, Merck, and Roche; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, Stendhal, and ECTRIMS; speaking honoraria from Sanofi and Merck; and is a member of the International Women in Multiple Sclerosis (iWiMS) network executive committee. https://orcid.org/0000-0002-2657-5510. Dr R.A.B. has served as a consultant for Biogen, EMD Serono, Genzyme/Sanofi, Genentech/Roche, Novartis, and Viela Bio. He receives ongoing research support directed to his institution from Biogen, Genentech, and Novartis. Mr P.C.-M.’s yearly salary is supported by a grant from Biogen to Fundació privada CEMCAT toward statistical analysis, and he has received travel expenses from Biogen. Dr S.C.-R. is an ECTRIMS clinical fellowship awardee; he has received travel expenses for scientific meetings from Biogen Idec and Genzyme, compensation for consulting services or participation in advisory boards from Roche and Novartis, and speaking honoraria from Novartis. https://orcid.org/0000-0002-7612-3985. Dr J.A.C. received personal compensation for consulting for Adamas, Convelo, MedDay, and Mylan; and serving as an editor of Multiple Sclerosis Journal. Ms M.D. has nothing to disclose. Dr K.C.F. is supported by NIMH K01 MH121582 and a Career Transition Fellowship from the National MS Society. Ms K.H. has nothing to disclose. Dr L.H.H. has received speaking and consulting fees from Biogen, Genzyme, Genentech, Novartis, Bristol Myers Squibb, and EMD Serono. Mr T.H. has nothing to disclose. Mr S.H. has nothing to disclose. Dr K.R.M. is funded by NIH NINDS K23 Career Development Award 1K23NS109328. Dr M.P.M. has served on scientific advisory boards for Genzyme and Genentech, research support from Novartis, and receives funding from a KL2 (KL2TR002547) grant from Clinical and Translational Science Collaborative of Cleveland, from the National Center for Advancing Translational Sciences (NCATS) component of the NIH. Dr X.M. received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, MedDay, Merck, MSIF, Nervgen, NMSS, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceuticals, and TG Therapeutics. https://orcid.org/0000-0002-0098-9918. Dr B.P.M. reports research funding for investigator-initiated studies from Roche and is site PI for studies sponsored by Roche; he received speaking fees from Genzyme, consulting fees for Roche, and has stock in Pfizer. Dr E.L.M. reports research funding for investigator-initiated studies from Biogen, Sanofi-Genzyme, and Teva, and is site PI for studies sponsored by Biogen. She received royalties for editorial duties for UpToDate. Ms E.O. has nothing to disclose. Dr D.O. has received research support from the National Institutes of Health, National Multiple Sclerosis Society, Patient Centered
Outcomes Research Institute, Race to Erase MS Foundation, Genentech, Genzyme, and Novartis. He has also received consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Novartis, and Merck. Ms M.R.-B. has nothing to disclose. Dr J.S.-G. has received compensation for participating on Advisory Boards, speaking honoraria and travel expenses for scientific meetings, consulting services or research support from Celgene, Novartis, Biogen, Teva, Merck, Almirall, and Genzyme. https://orcid.org/0000-0002-1589-2254. Dr P.T. is an ECTRIMS clinical fellowship awardee and has received travel expenses for scientific meetings from Roche. https://orcid.org/0000-0002-4048-7314. Dr M.T. has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. Dr M.T. is coeditor of Multiple Sclerosis Journal—Experimental, Translational and Clinical. https://orcid.org/0000-0001-9999-5359. Ms Z.W. has nothing to disclose. Ms M.W. has nothing to disclose. Dr A.Z. has received travel expenses for scientific meetings from Biogen Idec, Novartis, and Genzyme; speaking honoraria from Eisai; and a study grant from Novartis. https://orcid.org/0000-0003-3860-5251.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The development of standardized data collection as part of routine clinical care through Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) was developed and implemented at CC, JH, and CEMCAT in partnership with Biogen. Biogen did not have involvement in study design, data analysis or interpretation, or manuscript preparation.

**ORCID iDs**

Brandon P Moss [D](https://orcid.org/0000-0001-5319-5129)
Kedar R Mahajan [D](https://orcid.org/0000-0002-0339-9876)
Le H Hua [D](https://orcid.org/0000-0002-0535-3978)
Daniel Ontaneda [D](https://orcid.org/0000-0002-2838-9148)
Ana Zabalza [D](https://orcid.org/0000-0003-3860-5251)
Georgina Arrambide [D](https://orcid.org/0000-0002-2657-5510)
Jaume Sastre-Garriga [D](https://orcid.org/0000-0002-1589-2254)
Mar Tintore [D](https://orcid.org/0000-0001-9999-5359)
Jeffrey A Cohen [D](https://orcid.org/0000-0001-9245-9772)

**References**

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard, covid19.who.int/ (2020, accessed 7 July 2020).

2. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. *JAMA Neurol*. Epub ahead of print 26 June 2020. DOI: 10.1001/jamaneurol.2020.2581.

3. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; 42(2): 377–381.

4. Baldassari LE, Nakamura K, Moss BP, et al. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. *Mult Scler Relat Disord* 2020; 38: 101525.

5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983; 33(11): 1444–1452.

6. Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. *BMC Neurol* 2013; 13(1): 37.

7. Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30 day rehospitalizations: an analysis of Medicare data. *Ann Intern Med* 2014; 161(11): 765–774.

8. R Core Team. R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, 2019, http://www.R-project.org/

9. Sastre-Garriga J, Tintore M and Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. *Mult Scler* 2020; 26(10): 1153–1156.

10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395(10229): 1054–1062.
11. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21(3): 335–337.

12. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(13): 382–386.

13. National Multiple Sclerosis Society. MS treatment guidelines during coronavirus, nationalmssociety.org/ (2020, accessed 2 July 2020).

14. Multiple Sclerosis International Federation. Global COVID-19 advice for people with MS, msif.org/ (2020, accessed 2 July 2020).

15. World Health Organization. COVID-19 significantly impacts health services for noncommunicable diseases, who.int/news-room/detail/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases (2020, accessed 2 July 2020).

16. Jehi L, Ji X, Milinovich A, et al. Individualizing risk prediction for positive COVID-19 testing: Results from 11,672 patients. *Chest*. Epub ahead of print 10 June 2020. DOI: 10.1016/j.chest.2020.05.580.